Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?

Cardiovasc Drugs Ther. 2017 Feb;31(1):1-3. doi: 10.1007/s10557-017-6720-7.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acute Coronary Syndrome*
  • Cost-Benefit Analysis
  • Humans
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors

Substances

  • Platelet Aggregation Inhibitors